COVID-19 Clinical Trial
— TRAINCOVIDOfficial title:
Cognitive Rehabilitation in Post-COVID-19 Condition: A Study Protocol for a Randomized Controlled Trial
Post-COVID-19 condition is frequently comprised of persistent cognitive sequela, including deficits in attention and executive functions (EFs). Goal Management Training (GMT) is a cognitive rehabilitation (CR) intervention for improving attention and EFs that has received empirical support in studies of other patient groups. The present study aims to determine the efficacy of GMT for improving everyday attention and EFs in adults who experience persistent cognitive deficits after COVID-19. The study is a randomized controlled trial (RCT), comparing the efficacy of GMT to a wait list control condition (WL), for improving persistent cognitive sequela in post-COVID-19 condition. The study aims to recruit 240 participants aged 18 to 65 years with a history of laboratory- or home-test confirmed, SARS-CoV-2 infection (> 3 months since infection) and perceived attentional and EF difficulties in daily life that have lasted for at least two months and that cannot be explained by an alternative diagnosis. Participants will be randomized to either group-based GMT (n = 120) or WL (n = 120). GMT will be internet-delivered to groups of six participants in six two-hour sessions delivered weekly (five weeks). The primary outcome will be the Metacognition Index of the Behavior Rating Inventory of Executive Function - Adult Version, a self-report measure assessing everyday EF difficulties, at six months post-treatment. Secondary outcomes include performance-based neurocognitive measures and rating scales of cognition, emotional health, quality of life, and fatigue. Secondary aims include to explore to what extent potential early change predicts outcome, and to examine what characterize those who profit from GMT, in addition to describe the neurocognitive and emotional health in a Covid-19 sample. The investigators will also examine potential effects of GMT at 2- and 5-year follow-up.
Status | Recruiting |
Enrollment | 240 |
Est. completion date | January 2029 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - history of laboratory- or home-test confirmed, SARS-CoV-2 infection (> 3 months since infection) - perceived cognitive difficulties (attention, memory, EF) affecting everyday functioning that have lasted for at least two months and that cannot be explained by an alternative diagnosis - age between 18-65 years Exclusion Criteria: - ongoing alcohol- or substance abuse, premorbid insult and/or comorbid neurological disease, severe neurocognitive problems interfering with the capacity to participate, sensory disorders biasing cognitive assessment, psychotic disorders, lack of proficiency in Norwegian, and being previously enrolled in a GMT trial. |
Country | Name | City | State |
---|---|---|---|
Norway | Lovisenberg Diaconal Hospital | Oslo |
Lead Sponsor | Collaborator |
---|---|
Lovisenberg Diakonale Hospital | Icahn School of Medicine at Mount Sinai, Oslo University Hospital, UiT The Arctic University of Norway, University of Oslo, University of Toronto |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Metacognition Index from the Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) | Self-report measure of daily life executive function (metacognition). Range:70-210. Higher score indicate greater executive dysfunction. | Change from baseline up to 6 months | |
Secondary | The Behaviour regulation Index from Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) | Self-report measure of daily life executive function (behaviour regulation). Range: 70-210. Higher score indicate greater executive dysfunction. | Change from baseline up to 6 months | |
Secondary | Cambridge Neuropsychological Test Automated Battery (CANTAB), subtests: the Stop Signal Task, Spatial Working Memory, Intra-Extra Dimensional Set Shift and Rapid Visual Information Processing | Performance-based neurocognitive test battery | Change from baseline up to 6 months | |
Secondary | The Hospital Anxiety and Depression Scale | Self-report measure of symptoms of anxiety and depression. The maximum score is 21 for depression and 21 for anxiety, range 0-21 on each scale. A higher score = more symptoms. | Change from baseline up to 6 months | |
Secondary | The Generalized Self-Efficacy Scale | Self-report measure of self-efficacy. Range:10-40. Higher score indicate higher self-efficacy. | Change from baseline up to 6 months | |
Secondary | Fatigue Severity Scale | Self-report measure of fatigue. 7 items. Range 7-49. Higher score indicate more fatigue. | Change from baseline up to 6 months | |
Secondary | The Perceived Deficits Questionnaire | Self-report measure of daily-life cognitive difficulties. The total score range from 0 to 80, with a higher score indicating greater perceived cognitive impairment. | Change from baseline up to 6 months | |
Secondary | Everyday Memory Questionnaire | Self-report measure of daily-life cognitive difficulties. The total score range from 0 to 52, with a higher score indicating greater perceived cognitive impairment. | Change from baseline up to 6 months | |
Secondary | RAND 12-Item Health Survey (RAND-12) | Self-report measure of quality of life. Range 0-10; a high score defines a more favorable health state. | Change from baseline up to 6 months | |
Secondary | EuroQol five-dimension scale questionnaire (EQ-5D) | Self-report measure of quality of life. The range of the EQ-5D index scores is 0 to 1 (1 indicates the best health state), but negative scores as low as-0.59 are possible for health states deemed to be worse than death. | Change from baseline up to 6 months | |
Secondary | DUKE-UNC Functional Social Support Questionnaire (FSSQ) | Self-report measure of social support. 8 items. The total score range from 8 to 40. Higher score indicates more social support. | Change from baseline up to 6 months | |
Secondary | DePaul Symptom Questionnaire short version | Self-report measure of fatigue symptoms. 14 items. The total score range from 0 to 56 for both frequency and severity for each item. | Change from baseline up to 6 months | |
Secondary | The Resilience Scale for Adults | Self-report measure of resilience. 33 items. The total score range from 33 to 165 | Change from baseline up to 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|
||
Recruiting |
NCT05200832 -
Impact of Long COVID-19 on the Health and Quality of Life of Military Personnel (Active or Retired) and Their Families
|